- Home
- MNOV vs IMMX Comparison
MNOV vs IMMX Comparison
Compare MNOV & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- IMMX
- Stock Information
- Founded
- MNOV 2000
- IMMX 2014
- Country
- MNOV United States
- IMMX United States
- Employees
- MNOV N/A
- IMMX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- MNOV Health Care
- IMMX Health Care
- Exchange
- MNOV Nasdaq
- IMMX Nasdaq
- Market Cap
- MNOV 76.0M
- IMMX 82.6M
- IPO Year
- MNOV 2005
- IMMX 2021
- Fundamental
- Price
- MNOV $1.43
- IMMX $4.02
- Analyst Decision
- MNOV Strong Buy
- IMMX Strong Buy
- Analyst Count
- MNOV 2
- IMMX 1
- Target Price
- MNOV $7.00
- IMMX $8.00
- AVG Volume (30 Days)
- MNOV 3.0M
- IMMX 842.3K
- Earning Date
- MNOV 11-12-2025
- IMMX 11-07-2025
- Dividend Yield
- MNOV N/A
- IMMX N/A
- EPS Growth
- MNOV N/A
- IMMX N/A
- EPS
- MNOV N/A
- IMMX N/A
- Revenue
- MNOV $257,917.00
- IMMX N/A
- Revenue This Year
- MNOV N/A
- IMMX N/A
- Revenue Next Year
- MNOV N/A
- IMMX N/A
- P/E Ratio
- MNOV N/A
- IMMX N/A
- Revenue Growth
- MNOV N/A
- IMMX N/A
- 52 Week Low
- MNOV $1.13
- IMMX $1.34
- 52 Week High
- MNOV $2.48
- IMMX $4.60
- Technical
- Relative Strength Index (RSI)
- MNOV 51.43
- IMMX 61.20
- Support Level
- MNOV $1.41
- IMMX $3.16
- Resistance Level
- MNOV $1.63
- IMMX $4.60
- Average True Range (ATR)
- MNOV 0.10
- IMMX 0.43
- MACD
- MNOV -0.01
- IMMX 0.04
- Stochastic Oscillator
- MNOV 6.90
- IMMX 66.83
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.